Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters

Nuclear Medicine and Biology

Volumn 23, Issue 4, 1996, Pages 467-471

  Kilbourn, Michael R ^a,b   Frey, Kirk A ^a   Vander Borght, Thierry ^a   Sherman, Phillip S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Dopamine; In vivo; Mouse; Transporter; Vesicular

Indexed keywords

DIHYDROTETRABENAZINE; HALOPERIDOL; PARGYLINE; RESERPINE; SELEGILINE; TETRABENAZINE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROTRANSMISSION; PHARMACOKINETICS; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030152867     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(96)00023-6     Document Type: Article

References (34)

1. 1. Buu N. T. (1989) Modification of vesicular dopamine and norepinephrine by monoamine oxidase inhibitors. Biochem. Pharmacol. 38, 1685-1692.
2. 2. Cumming P., Kuwabara H., Ase A. and Gjedde A. (1995) Regulation of DOPA decarboxylase activity in brain of living rat. J. Neurochem. 65, 1381-1390.
3. 11C]tetrabenazine to vesicular monoamine transporters in mouse brain. Life Sci. 51, 593-600.
4. 11C]tetrabenazine. Synapse 14, 128-131.
5. 11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter. Nucl. Med. Biol. 21, 151-156.
6. 11C]tetrabenazine, a vesicular monoamine uptake inhibitor, for PET imaging studies. Appl. Radiat. Isot. 44, 673-676.
7. 11C]methoxy derivative of α-dihydrotetrabenazine: A radioligand for studying the vesicular monoamine transporter. Appl. Radiat. Isot. 44, 673-676.
8. 8. Frey K. A., Koeppe R. A., Kilbourn M. R., Vander Borght T. M., Albin R. L., Gilman S. and Kuhl D. E. (1995) Reduction of presynaptic monoaminergic vesicles in the striata of Parkinsonian patients and in normal human aging. J. Cereb. Blood Flow Metab. 15, S38.
9. 11C]dihydrotetrabenazine and PET. J. Cereb. Blood Flow Metab. 15, S752.
10. 10. Gonzalez A. M., Walther D., Pazos A. and Uhl G. R. (1994) Synaptic vesicular monoamine transporter expression: Distribution and pharmacologic profile. Mol. Brain Res. 22, 219-226.
11. 11. Henry J.-P. and Scherman D. (1989) Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem. Pharmacol. 38, 2395-2404.
12. 11C]raclopride binding in rat striatum, quantified using PET. Synapse 21, 45-53.
13. 13. Kelly R. B. (1993) Storage and release of neurotransmitters. Cell 10(Suppl.), 43-53.
14. 14. Kilbourn M., Lee L., Vander Borght T., Jewett D. and Frey K. (1995) Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur. J. Pharmacol. 278, 249-252.
15. 15. Kilbourn M. R. (1994) PET radioligands for vesicular neurotransmitter transporters. Med. Chem. Res. 5, 113-126.
16. 11C]tetrabenazine and positron emission tomography. J. Neurochem. 60, 2315-2318.
17. 18F]GBR 13119 binding to the dopamine uptake site. Eur. J. Pharmacol. 216, 109-112.
18. 18. Kuczenski R. (1977) Differential effects of reserpine and tetrabenazine on rat striatal synaptosomal dopamine biosynthesis and synaptosomal dopamine pools. J. Pharmacol. Exp. Ther. 201, 357-367.
19. 19. Lee C.-M., Javitch J. A. and Snyder S. H. (1983) Regulation sites for norepinephrine uptake: Regulation by neurotransmitter. Science 220, 626-628.
20. 20. Lehericy S., Brandel J.-P., Hirsch E. C., Anglade P., Villares J., Scherman D., Duyckaerts C., Javoy-Agid F. and Agid Y. (1994) Monoamine vesicular uptake sites in patients with Parkinson's and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res. 659, 1-9.
21. 21. Mehvar R., Jamali F., Watson M. W. B. and Skelton D. (1987) Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Drug Metab. Dispos. 15, 250-255.
22. 22. Naudon L., Leroux-Nicollet I. and Costentin J. (1994) Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neurosci. Lett. 173, 1-4.
23. 23. Naudon L., Leroux-Nicollet I., Raisman-Vozari R., Botton D. and Costentin J. (1995) Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex. Synapse 21, 29-36.
24. 24. Opacka-Juffry J. and Brooks D. J. (1995) L-Dihydroxyphenylalanine and its decarboxylase: New ideas on their neuroregulatory roles. Mov. Disord. 10, 241-249.
25. 3H-raclopride in the mouse brain in vivo. Naunyn-Schmeidebergs Arch. Pharmacol. 340, 6-12.
26. 26. Rostene W., Boja J. W., Scherman D., Carroll F. I. and Kuhar M. J. (1992) Dopamine transport: Pharmacological distinction between the synaptic membrane and the vesicular transporter in rat striatum. Eur. J. Pharmacol. 218, 175-177.
27. 27. Scheffel U., Steinert C. L., Kuhar M. J. and Neumeyer J. L. (1991) Effect of endogenous dopamine on 3H WIN 35,428 binding to dopamine uptake sites. J. Nucl. Med. 32, 1069.
28. 28. Scherman D. (1986) Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J. Neurochem. 47, 331-339.
29. 29. Scherman D., Desnos C., Darchen F., Pollak P., Javoy-Agid F. and Agid Y. (1989) Striatal dopamine deficiency in Parkinson's disease; role of aging. Ann. Neurol. 26, 551-557.
30. 30. Vander Borght T. M., Desmond T. J., Kilbourn M. R., Albin R. L., Koeppe R. A., Kuhl D. E. and Frey K. A. (1995a) Evaluation of methoxytetrabenazine as an in vivo tracer of monoamine nerve terminal integrity. J. Nucl. Med. 36, 2252-2260.
31. 31. Vander Borght T. M., Kilbourn M. R., Desmond T. J., Kuhl D. E. and Frey K. A. (1995b) The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 294, 577-583.
32. 3H]Methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68, 955-962.
33. 3H]GBR 12783 binding in vivo. Eur. J. Pharmacol. 178, 221-227.
34. 34. Wilson J. M., Carroll M. E. and Kish S. J. (1995) The vesicular monoamine transporter, in contrast to the dopamine transporter, is not regulated following chronic cocaine self-administration. Soc. Neurosci. Abstr. 21, 1382.